Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Deborah Collyar: What's In It for Patients?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Varsha Gandhi, PhD, on Ibrutinib

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Apr
23
Today In Oncology
Long-Term Immunotherapy for Alveolar Soft Part Sarcoma
AMA Data Show Nearly 50 Percent of Surveyed Oncologists Reported Burnout in 2025
Unique Phase I NSCLC Trial Sites Decreasing in United States
Overall Survival With Addition of Relacorilant to Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer
Tislelizumab With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo